Annual report
4886.TEDINET S100R645
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥5.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 747 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥658m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥603m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥591m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥630m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 79 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 14 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥298m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥220m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥481m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥77m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥43.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Animal Health Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Animal Health Businessreportable segment | employees | at 2023-03-31 | 36 pure |
| Animal Health Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2023-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥409m |
| Pharmaceutical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 610 pure |
| Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥53.6bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2023-03-31 | ¥40.1bn |
| Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥60.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥77m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥43.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥259m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥185m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥90m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Animal Health Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4m |
| Animal Health Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Animal Health Businessreportable segment | segment assets | at 2022-03-31 | ¥3.0bn |
| Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥376m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,440
| Item | Context | Value | Unit |
|---|---|---|---|
| Policy on human resource development and improvement of internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Reference to other information strategy human capital | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on human resource development and improvement of internal environment and targets and results using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Reference to other information metrics and targets human capital | FilingDateInstant | Text · Plus | |
| Reference to other information2 metrics and targets human capital | FilingDateInstant | Text · Plus | |
| Reference to other information metrics and targets | FilingDateInstant | Text · Plus | |
| Reference to other information3 metrics and targets human capital | FilingDateInstant | Text · Plus | |
| Reference to other information4 metrics and targets human capital | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区浜松町２丁目11番３号 | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)武田薬品工業株式会社 | |
| Address major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)大阪市中央区道修町４丁目１－１ | |
| Name major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)ゼリア新薬工業株式会社 | |
| Address major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋小舟町10番11号 | |
| Name major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８－12 | |
| Name major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)株式会社三菱ＵＦＪ銀行 | |
| Address major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目７番１号 | |
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)山口隆 | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)横浜市港北区 | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)株式会社ヤマグチ | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東京都港区三田３丁目１番10号三田マルハチビル６Ｆ | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)あいおいニッセイ同和損害保険株式会社（常任代理人 日本マスタートラスト信託銀行株式会社） | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)東京都渋谷区恵比寿１丁目28番１号（東京都港区浜松町２丁目11番３号） | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)日本生命保険相互会社（常任代理人 日本マスタートラスト信託銀行株式会社） | |
| Address major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内１丁目６番６号（東京都港区浜松町２丁目11番３号） | |
| Name major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)トーア再保険株式会社 | |
| Address major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区神田駿河台３丁目６番地の５ | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |